Full-Time

Director IT & Business Enablement

Dispatch Biotherapeutics

Dispatch Biotherapeutics

51-200 employees

Cloud-based software linking labs and providers

No salary listed

Philadelphia, PA, USA

In Person

Travel to the San Francisco office up to 25% of the time.

Bachelor's

Category
IT & Security (1)
Required Skills
Microsoft Azure
ERP
ETL
Human Resources Information System (HRIS)
AWS
Data Governance
Google Cloud Platform

Get referred to Dispatch Biotherapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree.
  • At least 10 years of IT experience, including at least 3 years in a biotech or pharmaceutical environment, ideally at the clinical stage.
  • Working knowledge of GxP and GCP requirements for electronic systems, including computer system validation, 21 CFR Part 11, and ALCOA+ data integrity.
  • Experience managing or overseeing managed service providers and third-party IT vendors, including service-level agreement accountability and vendor governance.
  • Strong knowledge of business applications strategy, including evaluating, deploying, and managing enterprise software such as human resources information systems, enterprise resource planning systems, laboratory information management systems, quality systems, and collaboration tools.
  • Hands-on experience enabling Amazon Web Services and/or Microsoft Azure cloud computing environments for scientific or technical users, with emphasis on self-service models and cost governance.
  • Understanding of data governance, data privacy, and information security in a regulated biotech or pharmaceutical context.
  • Working knowledge of artificial intelligence tools and platforms and their integration into enterprise business processes.
  • Ability to operate as both a strategic thinker and a hands-on operator in a lean, fast-moving environment.
  • Ability to translate technical concepts for non-technical audiences and manage stakeholder relationships.
  • Strong project management and organizational skills, with ability to manage multiple priorities simultaneously.
  • Ability to travel approximately 25% of the time, typically to the San Francisco office.
Responsibilities
  • Own and maintain a company-wide applications roadmap that balances near-term needs with a scalable, cost-effective architecture.
  • Lead the evaluation, selection, and deployment of enterprise applications, including change management, user adoption, and technology intake and governance.
  • Own the organization's information security posture and coordinate managed service providers and specialist providers to maintain an audit-ready security program.
  • Establish and maintain identity and access management, including single sign-on, multifactor authentication, and joiner/mover/leaver lifecycle processes, endpoint protection, and backup and disaster recovery.
  • Design and govern data architecture, storage, access controls, and lifecycle management for a clinical-stage biotech operating under GxP requirements.
  • Own data integrity and computer system validation for GxP-relevant systems, including 21 CFR Part 11, ALCOA+ principles, and audit-trail review.
  • Ensure data generated by laboratory instrumentation and scientific systems such as laboratory information management systems and electronic laboratory notebooks is captured, secured, and governed under appropriate controls.
  • Partner with research leads to understand evolving computational needs and plan capacity and tooling.
  • Develop and enforce IT policies and procedures reflecting regulatory requirements and operational realities.
  • Serve as the technical owner for partner and sponsor due diligence by completing security and quality questionnaires, supporting external audits, and maintaining inspection documentation.
  • Serve as the primary internal point of contact for the IT managed service provider to ensure service quality, accountability, prioritization, and continuous improvement.
  • Manage relationships with IT vendors and third-party service providers, conduct regular business reviews, and drive continuous improvement.
  • Develop and manage short- and long-term IT budgets across managed service provider services, software-as-a-service applications, cloud infrastructure, and security tools.
  • Ensure consistent IT service delivery across the Philadelphia and San Francisco offices.
  • Set the artificial intelligence architecture, data-handling guardrails, and acceptable-use policy.
  • Evaluate how artificial intelligence tools integrate with the existing technology stack and guide development of an AI-compatible data and application architecture.
Desired Qualifications
  • Experience building or scaling IT capabilities at a company transitioning from research stage to clinical stage.
  • Familiarity with systems supporting clinical trials and regulated workflows, including electronic trial master files, clinical trial management systems, and electronic quality management systems.
  • Hands-on involvement with enterprise artificial intelligence strategy, tool selection, and deployment in a regulated environment.
  • ITIL certification and/or Certified Information Systems Security Professional certification or an equivalent security credential.
  • Experience supporting big-pharma partnerships or sponsor audits, including preparing for and responding to partner security and quality due diligence.
Dispatch Biotherapeutics

Dispatch Biotherapeutics

View

Dispatch Bio provides a cloud-based software platform for infectious disease diagnostics. It connects patients, providers, and laboratories to deliver faster, more accurate test results. The core product is a SaaS system that laboratories use to manage test orders, workflows, and results reporting, while healthcare providers use it to order tests and receive timely results for patients. The platform integrates the entire diagnostic process in a single system, reducing turnaround times and streamlining communication across the care team. Compared with typical lab software, Dispatch Bio focuses on end-to-end workflow integration, strong data security and regulatory compliance, and a B2B model that targets diagnostic labs and healthcare providers. Its goal is to modernize diagnostic testing to enable quicker diagnoses and better patient management in infectious diseases.

Company Size

51-200

Company Stage

Series A

Total Funding

$216M

Headquarters

Philadelphia, Pennsylvania

Founded

2022

Get referred to Dispatch Biotherapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared DISP-10 IND in January 2026, removing the first major regulatory hurdle.
  • First patient dosed August 6, 2026, with Fast Track designation for advanced GI cancers.
  • ClinicalTrials.gov shows recruiting sites at City of Hope and Tennessee Oncology, supporting execution.

What critics are saying

  • DISP-10's biology is unproven clinically; a 66-patient Phase 1 starts in 2026.
  • Solid-tumor CAR-T faces toxicities, antigen escape, and manufacturing complexity that can stall enrollment.
  • If DV-10 or ide-cel underperform, Dispatch's universal-solid-tumor thesis collapses before proof-of-concept.

What makes Dispatch Biotherapeutics unique

  • Flare paints tumor-specific antigens with DV-10, enabling BCMA CAR-T to attack epithelial tumors.
  • BMS supplied ide-cel for Dispatch's 2026 Phase 1, validating platform credibility and access.
  • Company spans Philadelphia and San Francisco, backed by ARCH, PICI, and University of Pennsylvania.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Vision Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Apr 27th, 2026
Dispatch Bio's SEND T cell armoring strategy shows 200X+ therapeutic window in solid tumors

Dispatch Bio presented preclinical data on its SEND T cell armoring strategy at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston. The technology uses a synthetic cytokine receptor to simultaneously activate multiple pathways for optimal T cell function, designed to overcome limitations in the tumour microenvironment. Preclinical results showed SEND-armoured CAR T cells achieved tumour clearance at low doses with a therapeutic window exceeding 200-fold. The treatment demonstrated efficacy with or without lymphodepleting chemotherapy. Single-cell RNA sequencing revealed simultaneous enrichment of effector and memory gene programmes within individual cells, indicating robust expansion without exhaustion. Dispatch Bio believes SEND could apply broadly across engineered T cell approaches, including autologous CAR T therapies and TCR-based treatments. The company's Flare platform combines immunotherapy with tumour-specific virus engineering for solid tumour treatment.

BioSpace
Nov 5th, 2025
Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

Dispatch Bio unveils first clinical program and presents data supporting Flare platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. November 5, 2025 | Encouraging preclinical data validate Dispatch's scientific approach and support advancement of DISP-10 toward clinical development in 2026 PHILADELPHIA & SAN FRANCISCO-(BUSINESS WIRE)-Dispatch Bio, a biotechnology company developing a universal treatment for solid tumors, today announced preclinical data supporting its first therapeutic program planned to enter the clinic, DISP-10, and its first-in-class Flare platform, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Immunotherapies have had limited success in solid tumors due to the lack of tumor-specific targets and a profoundly immunosuppressive microenvironment. Dispatch's Flare platform addresses these barriers by systemically delivering a tumor-specific virus that paints a universal synthetic antigen (Flare) on tumor cells, enabling precise recognition by T cells, while reshaping the tumor microenvironment to support immune activity. Data presented at SITC (Abstract 394) demonstrate strong and consistent tumor labeling, iterative viral amplification and tumor cell clearance across multiple epithelial tumor models. "These data show that delivering engineered targets specifically to tumor cells allows us to control antigen specificity, while also reprogramming the tumor microenvironment," said Lex Johnson, Ph.D., Co-Founder and Chief Platform Officer. "We are excited to start with CAR T as our first program, and because the Flare approach is modular and not restricted to CAR T cells, it can be extended across multiple immunotherapy modalities." The company also presented preclinical findings from DISP-10, its first therapeutic candidate (Abstract 393). DISP-10 pairs DV-10, a tumor-targeted virus expressing a modified BCMA antigen (dBCMA) and the immune-stimulatory cytokine IL-18 and chemokine CXCL9, with a clinically validated BCMA-directed CAR T. The viral component installs the target and drives local immune activation, enabling robust CAR T function in solid tumors. DISP-10 demonstrated potent anti-tumor responses in numerous in vitro and in vivo models, with no activity observed in healthy cells. Dispatch plans to initiate a first-in-human Phase 1 study in 2026 to evaluate DISP-10 across multiple solid tumor types. "DISP-10 creates the right biological context for CAR T cells to function in solid tumors," said Barbra Sasu, Ph.D., Chief Scientific Officer. "The consistency of activity seen with various BCMA-targeted therapies across tumor models gives us confidence in its clinical potential." Dispatch also announced a clinical supply and collaboration agreement with Bristol Myers Squibb (BMS). Under the agreement, BMS will supply idecabtagene vicleucel (ide-cel) as the CAR T-cell component for Dispatch's first U.S. Phase 1 trial of DISP-10. DV-10, emerging from the Flare platform, provides the tumor-specific targeting and immune activation necessary for CAR T-cell function in solid tumors. Please see full Prescribing Information for idecabtagene vicleucel (ide-cel), including Boxed WARNINGS and Medication Guide. About Dispatch Bio Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific virus, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers. To learn more, visit www.dispatchbio.com and follow us on LinkedIn and X.

Fierce Biotech
Jul 23rd, 2025
Cancer biotech Dispatch unveils with $216M and CAR-T pioneer Carl June as cofounder

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach.